| Title | Eletriptan treatment of migraine in patients switching from barbiturate-containing analgesics: results from a multiple-attack study. | | Author(s) | Martin VT, Loder E, Taylor K, Almas M, Hilliard B | | Institution | Division of General Internal Medicine, University of Cincinnati, Cincinnati, OH 452674217, USA. martindoc@pol.net | | Source | Cephalalgia 2005 Sep; 25(9):726-34. | | MeSH | Acetaminophen
Adolescent
Adult
Analgesics
Aspirin
Barbiturates
Caffeine
Drug Combinations
Female
Humans
Indoles
Male
Middle Aged
Migraine Disorders
Patient Satisfaction
Pyrrolidines
Quality of Life
Research Support, Non-U.S. Gov't
Serotonin Agonists
Treatment Outcome
Tryptamines
| | Abstract | The aim of this study was to examine efficacy and tolerability of eletriptan in patients switched from barbiturate-containing combinations (Fiorinal), Fioricet. Migraineurs (n = 160) meeting IHS criteria, with unsatisfactory response in the past year to butalbital-containing combinations, treated up to 16 attacks over 3 months with eletriptan 40 mg. Assessments included headache response and pain-free rates and functional impairment at baseline and 2 h postdose, and global ratings of treatment satisfaction at 24 h. At 2 h postdose, average headache response and pain-free rates were 71% (95% CI, 69-74%) and 37% (95% CI, 35-40%), respectively; 68.5% of patients (95% CI, 65-72%) reported functional response. Within-patient analysis found no efficacy diminution over time (no tolerance). Average headache recurrence rate was 20% (95% CI, 18-23%). Eletriptan was well-tolerated; 6 (3.7%) patients discontinued due to adverse events. There were no serious treatment-related adverse events. We conclude that in poor responders to butalbital-caffeine combinations, switching to eletriptan 40 mg was well-tolerated and efficacious. | | Language | eng | | Pub Type(s) | Clinical Trial
Journal Article
Multicenter Study
| | PubMed ID | 16109055 |
|
